These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Investing in Malaysia's largest clinic operator to expand the healthcare business
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Subscribe To Our Newsletter & Stay Updated
